Nicotine - People Living With Disabilities: Difference between revisions

← Older edit

VisualWikitext

@@ Line 10: / Line 10: @@
 *** Acknowledgments: This research was conducted independently without funding from any specific grant or organization. The open access publication fee was covered by the University of Glasgow through their agreement with Elsevier. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
-='''SMOKING PREVALENCE and DISPARITIES'''=
+='''PREVALENCE'''=
+===2025: Article [https://www.cdc.gov/disability-and-health/conditions/cigarette-smoking.html Cigarette Smoking among Adults with Disabilities]===
+*Current cigarette smoking is significantly higher among adults with a disability (27.8%) compared to adults without a disability (13.4%). The percentage of adults with disabilities using E-cigarettes is also higher (8%) compared to adults without disabilities (3.9%).
+**CDC
 ===2022: [https://pmc.ncbi.nlm.nih.gov/articles/PMC9930180/ Trends in Cigarette Smoking Prevalence and Status among U.S. Adults with Disabilities, 2015–2019]===
 *The prevalence of cigarette smoking among people with any disability is decreasing over time but remains higher than those without. People with any disability have similar odds of former smoking and differences exist by disability domain. Future research should explore additional smoking and quit behaviors by disability functioning domain.
@@ Line 33: / Line 37: @@
 ='''INCLUSION'''=
+===2024: Article [https://research.uky.edu/news/improving-tobacco-use-research-treatments-people-disabilities Improving tobacco use research, treatments for people with disabilities]===
+*Regnier points out that the health equity problem at hand is not simply a shortage of tailored treatment options — there’s also a dearth of research on smoking among people with IDD. He recently conducted a literature review that found only two published papers on the topic of smoking cessation treatment for this population in the U.S. In an effort to address this gap in knowledge, he’s now working as a post-doctoral fellow in the University of Kentucky College of Medicine’s Pharmacology of Addiction Lab (PAL), aiming to improve how smoking is assessed, measured and treated among people with IDD.
+**University of Kentucky
+***Since coming to UK, Regnier has received a pilot grant from the Department of Behavioral Science in the UK College of Medicine, an Early Career Investigator Award from the College on Problems of Drug Dependence (CPDD) and a travel award from CPDD as well.
 ===2022: [https://pmc.ncbi.nlm.nih.gov/articles/PMC9053313/ Creating a Tobacco Cessation Program for People with Disabilities: A Community Based Participatory Research Approach]===
 *The purpose of this study was to develop a tobacco cessation program designed by and for people with disabilities (PWD)...Community-Based Participatory Research (CBPR) was conducted to develop a tobacco cessation group treatment program for PWD.
@@ Line 39: / Line 48: @@
 ='''EXCLUSION'''=
+===2023: [https://pubmed.ncbi.nlm.nih.gov/34862325/ Inequity in smoking cessation clinical trials testing pharmacotherapies: exclusion of smokers with mental health disorders]===
+*We included 279 RCTs from 13 Cochrane reviews. Of all studies, 51 (18.3%) explicitly excluded participants with any MHDs, 152 (54.5%) conditionally excluded based on certain MHD criteria and 76 (27.2%) provided insufficient information to ascertain either inclusion or exclusion. Studies of antidepressant medications used for smoking cessation were found to be 3.33 times more likely (95% CI 1.38 to 8.01, p=0.007) to conditionally exclude smokers with MHDs than explicitly exclude compared with studies of nicotine replacement therapy.
+**Talukder SR, Lappin JM, Boland V, McRobbie H, Courtney RJ. Inequity in smoking cessation clinical trials testing pharmacotherapies: exclusion of smokers with mental health disorders. Tob Control. 2023 Jul;32(4):489-496. doi: 10.1136/tobaccocontrol-2021-056843. Epub 2021 Dec 3. PMID: 34862325; PMCID: PMC10314072.
+***The National Drug and Alcohol Research Centre at the University of New South Wales (UNSW), Australia, is supported by funding from the Australian Government under the Substance Misuse Prevention and Service Improvements Grants Fund and by infrastructure support from the UNSW, Australia. SRT is supported by a National Drug and Alcohol Research Centre PhD scholarship. RJC is supported by a National Health and Medical Research Council Career Development Fellowship. HM has received honoraria for speaking at smoking cessation meetings and attending advisory board meetings that have been organised by Pfizer.
 ===2019: [https://pmc.ncbi.nlm.nih.gov/articles/PMC6343546/ Reasons for Exclusion from a Smoking Cessation Trial: An Analysis by Race/Ethnicity]===
 *Study ineligibility, and reasons for exclusion (contraindications for nicotine patch use, serious mental illness [SMI, eg, bipolar disorder or schizophrenia], alcohol dependence or illicit drug use, current tobacco treatment, attendance barriers [eg, transportation], and other concerns [eg, aggressive, intoxicated, disruptive, visibly ill]).